BioRestorative Therapies, Inc. ("BRT" or the "Company")
(OTCBB:BRTX), a life sciences company focused on adult stem
cell-based therapies for various personal medical applications, today
announced that Wayne Olan, M.D has been appointed as a member of the
Company’s Scientific Advisory Board (“SAB”).
Dr. Olan, a board-certified Interventional Neuroradiologist, is the
director of endovascular and minimally invasive image guided
neurosurgery in Washington, D.C. at the George Washington University
Medical Center, and is also an associate professor at The George
Washington University School of Medicine & Health Sciences. Dr. Olan
also serves as a consulting physician to the National Institutes of
Health.
Dr. Olan was the director of interventional neuroradiology at Suburban
Hospital in Bethesda, Maryland from 1999 to 2010. He is a member of many
professional societies including the Radiological Society of North
America, American College of Radiology, American Medical Association,
Medical Society of District of Columbia, American Society of
Neuroradiology, and American Society of Spine Radiology.
Dr. Olan has over 150 published papers, posters, abstracts and lectures
on endovascular treatment of cerebrovascular disorders, including the
treatment of cerebral aneurysms, arteriovenous malformations, and the
treatment of stroke. A great deal of his research has covered the
interventional treatment of spinal disorders.
Dr. Wayne Marasco, Chairman of BRT’s Scientific Advisory Board said,
“Dr. Olan’s expertise in minimally invasive neurosurgery and spine
disease is a strong addition to the BRT team on several fronts. His
experience in interventional treatments for the spine is a welcome
addition to our SAB, and will prove invaluable as we prepare to file for
approval from the U.S. Food and Drug Administration to begin our
brtxDISC™ clinical trials for the treatment of protruding, bulging and
herniated lumbar discs.”
Dr. Olan received his M.D. degree from University of Health Science, the
Chicago Medical School. He completed his training in radiology and
fellowship training in neuroradiology with subspecialty training in
interventional neuroradiology.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com)
develops products and medical procedures using cell and tissue
protocols, primarily involving adult stem cells, including:
-
brtxDISC™ (Disc Implanted Stem Cells)
is an investigational non-surgical treatment for protruding, bulging
and herniated lumbar discs that is intended for patients who have
failed non-invasive procedures and face the prospect of surgery. The
treatment involves culturing a patient’s own stem cells and then
delivering them via a proprietary medical device to the damaged region
of the disc in an outpatient procedure.
-
ThermoStem® is a treatment using brown fat stem cells that is
under development for metabolic disorders including diabetes and
obesity. Initial preclinical research indicates that increased amounts
of brown fat in the body may be responsible for additional caloric
burning as well as reduced glucose and lipid levels.
-
brtx-C Cosmetic is based on the development of a human cellular
extract that has been demonstrated in in vitro skin studies to
increase the production of collagen and fibronectin, which are
proteins that are essential to combating the aging of skin. Potential
cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty
products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the Company undertakes no obligation to
update such statements.
Copyright Business Wire 2014